Baoyun Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Baoyun Xia has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin C. Blount
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
95 shared publications - Heather L. Kimmel
National Institute on Drug Abuse, National Institutes of Health , Bethesda, MD
92 shared publications - Lanqing Wang
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention , Atlanta, GA
92 shared publications - Cindy M. Chang
Center for Tobacco Products, Food and Drug Administration , Silver Spring, MD 20903
91 shared publications - Yuesong Wang
Centers for Disease Control and Prevention 5 Division of Laboratory Sciences, National Center for Environmental Health Atlanta, Georgia
90 shared publications - Jeffery Jarrett
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA
89 shared publications
Latest Publications
- 18 March 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (8) , 1444-1452
Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis
Background: The constituents of tobacco smoke that specifically contribute to lung cancer risk have yet to be fully identified. We evaluated associations between biomarkers of potentially harmful constituents—polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, nicotine, and volatile organic compounds—and lung cancer incidence among US women. Methods: In a case-cohort study nested within the Sister Study (women aged 35-74 years at baseline, enrolled 2003-2009), data were obtained for a random subcohort and all remaining incident lung cancers through September 2017 (median follow-up = 9.6 years), stratified by race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, others) and smoking status (current, former, never). The analytic sample included 356 cases and 433 noncases. We quantified 30 biomarkers in baseline urine samples and calculated hazard ratios (HRs) for associations between 1-unit increase in biomarker concentrations (log-scale) and lung cancer incidence using weighted Cox regression models adjusted for urinary creatinine and demographic, health, and lifestyle factors. Results: Among women who were currently smoking at enrollment, positive associations were observed for biomarkers of polycyclic aromatic hydrocarbons (naphthalene, phenanthrene, pyrene, fluorene; HRs = 1.4-5.3), tobacco-specific nitrosamines (particularly 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone [nicotine-derived nitrosamine ketone]; HRs = 1.3-2.2), and volatile organic compounds (xylene, acrylamide, acrylonitrile, 1,2-dibromoethane and/or vinyl-chloride and/or ethylene-oxide and/or acrylonitrile, acrolein, styrene and/or ethylbenzene, benzene, dimethylformamide and/or methylisocyanate, 1,3-butadiene, crotonaldehyde, isoprene; HRs = 1.6-4.4). Associations with biomarkers of most polycyclic aromatic hydrocarbons, nicotine-derived nitrosamine ketone, xylene, and dimethylformamide and/or methylisocyanate remained after additional adjustment for smoking frequency, duration, and nicotine metabolites. In women who did not smoke, positive associations were observed for styrene and/or ethylbenzene and dimethylformamide and/or methylisocyanate biomarkers. Conclusion: Exposure to polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and several volatile organic compounds through tobacco smoking were associated with increased lung cancer risk among women.
- 18 March 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (8) , 1444-1452
Tobacco-related urinary biomarkers and lung cancer risk in women, a case-cohort analysis
Background: The constituents of tobacco smoke that specifically contribute to lung cancer risk have yet to be fully identified. We evaluated associations between biomarkers of potentially harmful constituents—polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, nicotine, and volatile organic compounds—and lung cancer incidence among US women. Methods: In a case-cohort study nested within the Sister Study (women aged 35-74 years at baseline, enrolled 2003-2009), data were obtained for a random subcohort and all remaining incident lung cancers through September 2017 (median follow-up = 9.6 years), stratified by race and ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, others) and smoking status (current, former, never). The analytic sample included 356 cases and 433 noncases. We quantified 30 biomarkers in baseline urine samples and calculated hazard ratios (HRs) for associations between 1-unit increase in biomarker concentrations (log-scale) and lung cancer incidence using weighted Cox regression models adjusted for urinary creatinine and demographic, health, and lifestyle factors. Results: Among women who were currently smoking at enrollment, positive associations were observed for biomarkers of polycyclic aromatic hydrocarbons (naphthalene, phenanthrene, pyrene, fluorene; HRs = 1.4-5.3), tobacco-specific nitrosamines (particularly 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone [nicotine-derived nitrosamine ketone]; HRs = 1.3-2.2), and volatile organic compounds (xylene, acrylamide, acrylonitrile, 1,2-dibromoethane and/or vinyl-chloride and/or ethylene-oxide and/or acrylonitrile, acrolein, styrene and/or ethylbenzene, benzene, dimethylformamide and/or methylisocyanate, 1,3-butadiene, crotonaldehyde, isoprene; HRs = 1.6-4.4). Associations with biomarkers of most polycyclic aromatic hydrocarbons, nicotine-derived nitrosamine ketone, xylene, and dimethylformamide and/or methylisocyanate remained after additional adjustment for smoking frequency, duration, and nicotine metabolites. In women who did not smoke, positive associations were observed for styrene and/or ethylbenzene and dimethylformamide and/or methylisocyanate biomarkers. Conclusion: Exposure to polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, and several volatile organic compounds through tobacco smoking were associated with increased lung cancer risk among women.
- 24 May 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28 (3) , 412-421
Consistency of Biomarkers of Exposure in the Population Assessment of Tobacco and Health Study from Samples Taken 3 to 5 Years Apart
Introduction: Urinary biomarkers are useful in characterizing exposure to harmful and potentially harmful constituents of tobacco products and linking exposure to health outcomes. However, the consistency/reproducibility of many urinary biomarkers over long periods is unknown. Methods: Among people who exclusively used cigarettes in the Population Assessment of Tobacco and Health Study Waves 1, 2, 4, and 5 (ranging from 746 to 1361 subjects), we used weighted models to estimate variance components and intra-class correlation coefficients (ICC) for 15 biomarkers of exposure for urine samples collected 3–5 years apart, creatinine-only-adjusted and also adjusted for demographic and behavioral predictors. Results: In models adjusted only for creatinine, ICC values of biomarkers ranged from 0.41 (95% confidence interval (CI): 0.32, 0.49) (N-acetyl-S-(2-carbamoylethyl)-L-cysteine) to 0.73 (95% CI: 0.65, 0.81) (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol), varying within each chemical class. For models adjusted for predictors, associations between biomarkers and predictors were similar for samples collected 3–5 years and 1 year apart. Predictor-adjusted ICCs for samples collected 3–5 years apart ranged from 0.29 (95% CI: 0.17, 0.40) (N-Acetyl-S-(2-carbamoylethyl)-L-cysteine) to 0.63 (95% CI: 0.56, 0.69) (N-Acetyl-S-(2-hydroxyethyl)-L-cysteine) and appeared not different from those for samples collected 1 year apart. Conclusions: Even for 3 or 5 years between urine sample collection, unadjusted biomarkers of exposure showed fair to excellent reproducibility. Similar consistency between 1 year and 3–5 years between collections was found when including predictors in the model.
- 24 May 2025
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 28 (3) , 412-421
Consistency of Biomarkers of Exposure in the Population Assessment of Tobacco and Health Study from Samples Taken 3 to 5 Years Apart
Introduction: Urinary biomarkers are useful in characterizing exposure to harmful and potentially harmful constituents of tobacco products and linking exposure to health outcomes. However, the consistency/reproducibility of many urinary biomarkers over long periods is unknown. Methods: Among people who exclusively used cigarettes in the Population Assessment of Tobacco and Health Study Waves 1, 2, 4, and 5 (ranging from 746 to 1361 subjects), we used weighted models to estimate variance components and intra-class correlation coefficients (ICC) for 15 biomarkers of exposure for urine samples collected 3–5 years apart, creatinine-only-adjusted and also adjusted for demographic and behavioral predictors. Results: In models adjusted only for creatinine, ICC values of biomarkers ranged from 0.41 (95% confidence interval (CI): 0.32, 0.49) (N-acetyl-S-(2-carbamoylethyl)-L-cysteine) to 0.73 (95% CI: 0.65, 0.81) (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol), varying within each chemical class. For models adjusted for predictors, associations between biomarkers and predictors were similar for samples collected 3–5 years and 1 year apart. Predictor-adjusted ICCs for samples collected 3–5 years apart ranged from 0.29 (95% CI: 0.17, 0.40) (N-Acetyl-S-(2-carbamoylethyl)-L-cysteine) to 0.63 (95% CI: 0.56, 0.69) (N-Acetyl-S-(2-hydroxyethyl)-L-cysteine) and appeared not different from those for samples collected 1 year apart. Conclusions: Even for 3 or 5 years between urine sample collection, unadjusted biomarkers of exposure showed fair to excellent reproducibility. Similar consistency between 1 year and 3–5 years between collections was found when including predictors in the model.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary tables 1-7 from Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013–2014)
Table S1. Urinary BOEs in PATH Study Wave 1. Table S2. Urinary BOEs of Nicotine Metabolites in PATH Study Wave 1. Table S3. Urinary BOEs of TSNAs in PATH Study Wave 1. Table S4. Urinary BOEs of PAHs in PATH Study Wave 1. Table S5. Urinary BOEs of VOCs in PATH Study Wave 1. Table S6. Urinary BOEs of Metals in PATH Study Wave 1. Table S7. Urinary BOEs of Arsenic in PATH Study Wave 1.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary tables 1-7 from Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013–2014)
Table S1. Urinary BOEs in PATH Study Wave 1. Table S2. Urinary BOEs of Nicotine Metabolites in PATH Study Wave 1. Table S3. Urinary BOEs of TSNAs in PATH Study Wave 1. Table S4. Urinary BOEs of PAHs in PATH Study Wave 1. Table S5. Urinary BOEs of VOCs in PATH Study Wave 1. Table S6. Urinary BOEs of Metals in PATH Study Wave 1. Table S7. Urinary BOEs of Arsenic in PATH Study Wave 1.
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S30 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S30 shows the results of weighted multiple linear regression analysis of log-transformed urinary phenylglyoxylic acid (PhGA) with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S30 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S30 shows the results of weighted multiple linear regression analysis of log-transformed urinary phenylglyoxylic acid (PhGA) with study covariates
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S35 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S35 shows the results of weighted multiple linear regression analysis of log-transformed urinary N‐acetyl‐S‐(4‐hydroxy‐2‐methyl‐2‐buten‐1‐yl)‐L‐cysteine (4HMBeMA) with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S35 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S35 shows the results of weighted multiple linear regression analysis of log-transformed urinary N‐acetyl‐S‐(4‐hydroxy‐2‐methyl‐2‐buten‐1‐yl)‐L‐cysteine (4HMBeMA) with study covariates
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S22 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S22 shows the results of weighted multiple linear regression analysis of log-transformed urinary N‐acetyl‐S‐(1‐cyano‐2‐hydroxyethyl)‐L‐cysteine (1CyHEMA) with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S22 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S22 shows the results of weighted multiple linear regression analysis of log-transformed urinary N‐acetyl‐S‐(1‐cyano‐2‐hydroxyethyl)‐L‐cysteine (1CyHEMA) with study covariates
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S6 shows the results of weighted multiple linear regression analysis of log-transformed urinary trans-3’-hydroxycotinine with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S6 shows the results of weighted multiple linear regression analysis of log-transformed urinary trans-3’-hydroxycotinine with study covariates
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S36 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S36 shows the results of weighted multiple linear regression analysis of log-transformed urinary mandelic acid (MADA) with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S36 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S36 shows the results of weighted multiple linear regression analysis of log-transformed urinary mandelic acid (MADA) with study covariates
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S32 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S32 shows the results of weighted multiple linear regression analysis of log-transformed urinary N‐acetyl‐S‐(benzyl)‐L‐cysteine (BzMA) with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S32 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S32 shows the results of weighted multiple linear regression analysis of log-transformed urinary N‐acetyl‐S‐(benzyl)‐L‐cysteine (BzMA) with study covariates
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S24 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S24 shows the results of weighted multiple linear regression analysis of log-transformed urinary 3,4-methylhippuric acid (34MHA) with study covariates
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S24 from Influence of Half-life and Smoking/Nonsmoking Ratio on Biomarker Consistency between Waves 1 and 2 of the Population Assessment of Tobacco and Health Study
Supplementary Table S24 shows the results of weighted multiple linear regression analysis of log-transformed urinary 3,4-methylhippuric acid (34MHA) with study covariates